320 related articles for article (PubMed ID: 23373674)
1. Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men.
Rosen RC; Wu FC; Behre HM; Roehrborn CG; Schröder FH; Siami FS; Martha JF; Finn JD; Araujo AB
Aging Male; 2013 Mar; 16(1):1-7. PubMed ID: 23373674
[TBL] [Abstract][Full Text] [Related]
2. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
3. Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME).
Maggi M; Wu FC; Jones TH; Jackson G; Behre HM; Hackett G; Martin-Morales A; Balercia G; Dobs AS; Arver ST; Maggio M; Cunningham GR; Isidori AM; Quinton R; Wheaton OA; Siami FS; Rosen RC;
Int J Clin Pract; 2016 Oct; 70(10):843-852. PubMed ID: 27774779
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
5. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
7. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
Morales A
BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
[TBL] [Abstract][Full Text] [Related]
8. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
[TBL] [Abstract][Full Text] [Related]
9. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
[TBL] [Abstract][Full Text] [Related]
10. 12-month observation of testosterone replacement effectiveness in a general population of men.
Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
[TBL] [Abstract][Full Text] [Related]
11. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
12. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS).
Blick G; Khera M; Bhattacharya RK; Nguyen D; Kushner H; Miner MM
Pain Med; 2012 May; 13(5):688-98. PubMed ID: 22536837
[TBL] [Abstract][Full Text] [Related]
13. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
Kaplan AL; Hu JC
Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
Gould DC; Feneley MR; Kirby RS
BJU Int; 2006 Jul; 98(1):1-4. PubMed ID: 16831134
[TBL] [Abstract][Full Text] [Related]
15. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
Behre HM; Heinemann L; Morales A; Pexman-Fieth C
Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
17. Testosterone replacement therapy for late-onset hypogonadism.
Cunningham GR
Nat Clin Pract Urol; 2006 May; 3(5):260-7. PubMed ID: 16691239
[TBL] [Abstract][Full Text] [Related]
18. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism.
Kaminetsky JC; Moclair B; Hemani M; Sand M
J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402
[TBL] [Abstract][Full Text] [Related]
19. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
20. Testosterone administration in older men.
Matsumoto AM
Endocrinol Metab Clin North Am; 2013 Jun; 42(2):271-86. PubMed ID: 23702401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
